Key Points
- CEO Grigorios Siokas bought 61,614 shares on Nov. 19 at $0.65 (≈$40,049) and an additional 51,315 shares on Nov. 20 at $0.62, leaving him with 6,220,498 shares — roughly a 1.0% increase in his position.
- Cosmos Health trades around $0.65 (market cap ~$22.7M) but reported Q3 EPS of ($0.17) that missed estimates, has negative margins and high volatility, and carries a consensus analyst rating of "Sell".
Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas acquired 61,614 shares of the firm's stock in a transaction that occurred on Wednesday, November 19th. The stock was acquired at an average price of $0.65 per share, for a total transaction of $40,049.10. Following the completion of the acquisition, the chief executive officer directly owned 6,220,498 shares of the company's stock, valued at $4,043,323.70. The trade was a 1.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Grigorios Siokas also recently made the following trade(s):
- On Thursday, November 20th, Grigorios Siokas bought 51,315 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.62 per share, with a total value of $31,815.30.
Cosmos Health Trading Up 4.1%
NASDAQ:COSM traded up $0.03 on Friday, reaching $0.65. The company's stock had a trading volume of 73,739 shares, compared to its average volume of 612,892. Cosmos Health Inc. has a 12-month low of $0.28 and a 12-month high of $1.32. The stock has a 50 day moving average price of $0.94 and a 200 day moving average price of $0.71. The firm has a market cap of $22.66 million, a price-to-earnings ratio of -0.87 and a beta of 5.32. The company has a quick ratio of 0.82, a current ratio of 0.99 and a debt-to-equity ratio of 0.25.
Cosmos Health (NASDAQ:COSM - Get Free Report) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.16). Cosmos Health had a negative return on equity of 33.19% and a negative net margin of 31.01%.The business had revenue of $17.11 million for the quarter, compared to analyst estimates of $16.40 million. On average, equities analysts anticipate that Cosmos Health Inc. will post -0.78 EPS for the current fiscal year.
Institutional Investors Weigh In On Cosmos Health
A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC grew its stake in Cosmos Health Inc. (NASDAQ:COSM - Free Report) by 133.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 225,507 shares of the company's stock after buying an additional 128,776 shares during the quarter. Citadel Advisors LLC owned 0.65% of Cosmos Health worth $250,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 12.61% of the company's stock.
Analyst Ratings Changes
Several equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of Cosmos Health to a "hold" rating in a report on Saturday, September 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cosmos Health in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cosmos Health presently has a consensus rating of "Sell".
Get Our Latest Report on Cosmos Health
About Cosmos Health
(
Get Free Report)
Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
